Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Myeloid Sarcoma in a Patient with Myelodysplastic Syndrome Associated with del(5q-): Case Report and Literature Review.

Showalter JA, Tandon N, Zhao B, Tang G, Nguyen ND, Medeiros LJ.

Ann Clin Lab Sci. 2017 Aug;47(4):466-473. Review.

PMID:
28801374
2.

Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.

Stahl M, Zeidan AM.

Expert Rev Hematol. 2017 Apr;10(4):345-364. doi: 10.1080/17474086.2017.1297704. Epub 2017 Mar 9. Review.

PMID:
28277851
3.

Dyserythropoiesis of myelodysplastic syndromes.

Lefèvre C, Bondu S, Le Goff S, Kosmider O, Fontenay M.

Curr Opin Hematol. 2017 May;24(3):191-197. doi: 10.1097/MOH.0000000000000325. Review.

PMID:
28072603
4.

5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).

Ureshino H, Kizuka H, Kusaba K, Sano H, Nishioka A, Shindo T, Kubota Y, Ando T, Kojima K, Kimura S.

Int J Hematol. 2017 May;105(5):692-696. doi: 10.1007/s12185-016-2160-6. Epub 2016 Dec 2. Review.

PMID:
27914067
5.

Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.

Lian XY, Zhang ZH, Deng ZQ, He PF, Yao DM, Xu ZJ, Wen XM, Yang L, Lin J, Qian J.

PLoS One. 2016 Nov 8;11(11):e0165948. doi: 10.1371/journal.pone.0165948. eCollection 2016. Review.

6.
8.

Quality control mechanisms during ribosome maturation.

Karbstein K.

Trends Cell Biol. 2013 May;23(5):242-50. doi: 10.1016/j.tcb.2013.01.004. Epub 2013 Feb 1. Review.

Supplemental Content

Loading ...
Support Center